A Phase IA/B Study of SC-003 in Patients with Persistent Ovarian Cancer

Full Title

A Phase 1a/1b Dose Escalation and Expansion Study of SC-003 as a Single-Agent and in Combination with ABBV-181 in Subjects with Platinum-Resistant/ Refractory Ovarian Cancer


SC-003 is an investigational drug called an antibody-drug conjugate. It is composed of an antibody (which binds to a protein on cancer cells) and a drug that kills cancer cells.

In this study, researchers are evaluating the safety and preliminary effectiveness of SC-003 in women with ovarian cancer that has continued to grow despite platinum-containing therapy. SC-003 is given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have ovarian cancer that has continued to grow despite treatment that included cisplatin or carboplatin.
  • At least 3 weeks must pass between the completion of prior therapy and entry into the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Roisin O’Cearbhaill at 646-888-4227.